The presentation featured pooled 48-week data from two multicenter, randomized Phase II studies (Phase IIa, NCT06115993; Phase IIb, NCT06550128) in HBeAg-negative chronic hepatitis B (CHB) patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback